Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties

Angulo-Elizari, Eduardo; Henriquez-Figuereo, Andreina; Morán-Serradilla, Cristina; Plano, Daniel; Sanmartín, Carmen

doi:10.1016/j.ejmech.2024.116249

Cited by 3 publications

(1 citation statement)

References 388 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another important class of compounds recognized for their anticancer properties is 1,4-quinones [ 12 , 13 , 14 ]. Doxorubicin ( 5 ) ( Figure 2 ), for instance, is an anthracycline 1,4-quinone derivative that has been used clinically since the 1960s in chemotherapy for various cancer types [ 15 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Naphthoquinone-Quinolone Hybrids with Antitumor Effects on Breast Cancer Cell Lines—From the Synthesis to 3D-Cell Culture Effects

da Gama Oliveira,

Muxfeldt,

Muniz da Paz

et al. 2024

IJMS

View full text Add to dashboard Cite

Breast cancer stands as one of the foremost cause of cancer-related deaths globally, characterized by its varied molecular subtypes. Each subtype requires a distinct therapeutic strategy. Although advancements in treatment have enhanced patient outcomes, significant hurdles remain, including treatment toxicity and restricted effectiveness. Here, we explore the anticancer potential of novel 1,4-naphthoquinone/4-quinolone hybrids on breast cancer cell lines. The synthesized compounds demonstrated selective cytotoxicity against Luminal and triple-negative breast cancer (TNBC) cells, which represent the two main molecular types of breast cancer that depend most on cytotoxic chemotherapy, with potency comparable to doxorubicin, a standard chemotherapeutic widely used in breast cancer treatment. Notably, these derivatives exhibited superior selectivity indices (SI) when compared to doxorubicin, indicating lower toxicity towards non-tumor MCF10A cells. Compounds 11a and 11b displayed an improvement in IC50 values when compared to their precursor, 1,4-naphthoquinone, for both MCF-7 and MDA-MB-231 and a comparable value to doxorubicin for MCF-7 cells. Also, their SI values were superior to those seen for the two reference compounds for both cell lines tested. Mechanistic studies revealed the ability of the compounds to induce apoptosis and inhibit clonogenic potential. Additionally, the irreversibility of their effects on cell viability underscores their promising therapeutic utility. In 3D-cell culture models, the compounds induced morphological changes indicative of reduced viability, supporting their efficacy in a more physiologically relevant model of study. The pharmacokinetics of the synthesized compounds were predicted using the SwissADME webserver, indicating that these compounds exhibit favorable drug-likeness properties and potential as antitumor agents. Overall, our findings underscore the promise of these hybrid compounds as potential candidates for breast cancer chemotherapy, emphasizing their selectivity and efficacy.

show abstract